Sibylle Loibl

Sibylle Loibl leads the German Breast Group and has been central to multiple neoadjuvant TNBC trials including GeparSixto, GeparOcto, and BrighTNess studies. Her research has established the use of capecitabine for residual disease after neoadjuvant therapy and defined pCR as a surrogate endpoint for long-term outcomes in TNBC. She has contributed extensively to integrating PARP inhibitors and immunotherapy in neoadjuvant TNBC regimens. She is among the most productive clinical trial investigators in European breast cancer research.